MedPath

Portable Oxygen Concentrator to Improve Quality of Life in Chronic Obstructive Pulmonary Disease

Completed
Conditions
COPD
Registration Number
NCT01948544
Lead Sponsor
StratiHealth
Brief Summary

* Evaluate subjects in an prospective observational study

* Subjects will be administered scientifically validated questionnaires

* Determine the affect of the Portable Oxygen Concentrator (POC) on improvements in:

1. Exercise capability, dyspnea and quality of life as primary endpoints

2. Utilize:

1. Baseline Dyspnea Index (BDI)

2. Transitional Dyspnea Index (TDI)

3. Chronic Respiratory Disease Questionnaire (CRQ)

4. Six minute walk test (6MWT)

5. Epworth Sleepiness Scale (ESS)

* The secondary endpoints will be:

1. Rate of exacerbations, sleep quality

2. Health care utilization (emergency room encounters, hospital admissions)

Detailed Description

Evaluate subjects in an prospective observational study in which subjects will be screened and administered scientifically validated questionnaires at study entry and during the observation period at specified intervals to determine the affect of the Portable Oxygen Concentrator on improvements in exercise capability, dyspnea and quality of life as primary endpoints, utilizing the Baseline Dyspnea Index (BDI), Transitional Dyspnea Index (TDI), the Chronic Respiratory Disease Questionnaire (CRQ) and six minute walk test (6MWT). The secondary endpoints will be rate of exacerbations, sleep quality (reported as number of hours sleep improvement; utilize Epworth Sleepiness Scale \[ESS\]), and health care utilization (emergency room encounters, hospital admissions).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
27
Inclusion Criteria
  • Primary diagnosis of chronic obstructive pulmonary disease (COPD)
  • Clinically stable disease at the time of consent
  • Current prescription of oxygen; with previous or current oximetry suggesting desaturation at rest or during exercises (oxygen saturation ≤88% on at least one occasion)
  • Highest measured FEV1, 70% predicted; and
  • Highest measured FEV1/FVC, 70% predicted
  • Capable of giving informed consent
  • Currently using oxygen system that is either a portable tank; liquid or other Portable Oxygen Concentrator (POC)
  • Mobility without a walker, cane or rollator
  • Spo2 ≥ 92% on Portable Oxygen Concentrator (POC) at rest and activity
  • Non-smoker at time of consent
Exclusion Criteria
  • Cardiovascular disease as defined in New York Heart Association Functional Class III
  • Degenerative bone or joint disease that limits mobility and ability to perform activities of daily living and/or exercise
  • Current homeless persons
  • Active drug/alcohol dependence
  • Recent abuse history within the past two years
  • Clinically unstable at the time of consent
  • Currently a tobacco smoker

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Functional Capacity6 months

Change in functional capability, dyspnea - BDI/TDI

• Change in exercise capability - 6MWT

Quality of Life Using Chronic Respiratory Disease QuestionnaireMeasure Dyspnea at baseline upon study entry and change from baseline every two weeks up to three months; Numerical, 7-point modified Likert Scale; Total score and subscores on categories; higher scores indicate better health-related quality of life

Quality of life - Chronic Respiratory Disease Questionnaire

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (3)

Cardinal Medical Group

🇺🇸

Vista, California, United States

Tri-City Pulmonary Medical Group

🇺🇸

Oceanside, California, United States

Pathway Medical Group

🇺🇸

Westminster, California, United States

© Copyright 2025. All Rights Reserved by MedPath